Search Within

Dana Elizabeth Rathkopf

  1. "Tracy Smart-Curley"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (5)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Nursing (11)
  4. Solid Tumor Oncology Division (11)
  5. Hematologic Malignancies, Division of (6)
  6. GSK Faculty (5)

More Groups

People
  1. Tracy Smart-Curley (11)
  2. Howard Scher (9)
  3. Michael Morris (7)
  4. Susan Slovin (6)
  5. Daniel Danila (4)
  6. Glenn Heller (4)

More People

Years
  1. 2024 (1)
  2. 2021 (1)
  3. 2018 (1)
  4. 2016 (1)
  5. 2012 (3)
  6. 2011 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Annals of Oncology (1)
  3. British Journal of Cancer (1)
  4. Cancer Chemotherapy and Pharmacology (1)
  5. Investigational New Drugs (1)
  6. Molecular Cancer Therapeutics (1)
Publishers
  1. American Society of Clinical Oncology (6)
  2. Springer (2)
  3. American Association for Cancer Research (1)
  4. Nature Publishing Group (1)
  5. Oxford University Press (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
    Journal Article

    Graham, L.; Banda, K.; Torres, A.; Carver, B. S.; Chen, Y.; Pisano, K.; Shelkey, G.; Curley, T.; Scher, H. I.; Lotan, T. L.; more...
    Investigational New Drugs (2018)

    Fulltext@MSK | Save
  • A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Kuzel, T.; Cetnar, J. P.; Rathkopf, D. E.; Morris, M. J.; Alumkal, J. J.; Butler, A.; Curley, T.; Hullings, M.; Buddle, J. R.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I trial of docetaxel and pulse-dose 17-allylamino-17- demethoxygeldanamycin in adult patients with solid tumors
    Journal Article

    Iyer, G.; Morris, M. J.; Rathkopf, D.; Slovin, S. F.; Steers, M.; Larson, S. M.; Schwartz, L. H.; Curley, T.; Delacruz, A.; Ye, Q.; more...
    Cancer Chemotherapy and Pharmacology (2012)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Journal Article

    Rathkopf, D.; Carducci, M. A.; Morris, M. J.; Slovin, S. F.; Eisenberger, M. A.; Pili, R.; Denmeade, S. R.; Kelsen, M.; Curley, T.; Halter, M.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save